Price$118.67-0.15 (-0.13%)
01:30 PM07:45 PM
News · 26 weeks45-78%
2025-11-022026-04-26
Mix1990d
- Insider5(26%)
- Other5(26%)
- SEC Filings5(26%)
- Earnings2(11%)
- Leadership1(5%)
- Analyst1(5%)
Latest news
25 items- ANALYSTCitizens initiated coverage on Celcuity with a new price targetCitizens initiated coverage of Celcuity with a rating of Mkt Outperform and set a new price target of $150.00
- INSIDERSEC Form 4 filed by Nigon Richard4 - Celcuity Inc. (0001603454) (Issuer)
- SECSEC Form DEFA14A filed by Celcuity Inc.DEFA14A - Celcuity Inc. (0001603454) (Filer)
- SECSEC Form DEF 14A filed by Celcuity Inc.DEF 14A - Celcuity Inc. (0001603454) (Filer)
- INSIDERSEC Form 4 filed by Buller Richard E4 - Celcuity Inc. (0001603454) (Issuer)
- SECSEC Form 10-K filed by Celcuity Inc.10-K - Celcuity Inc. (0001603454) (Filer)
- SECCelcuity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Celcuity Inc. (0001603454) (Filer)
- PRCelcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateThe U.S. Food and Drug Administration ("FDA") accepted Celcuity's New Drug Application ("NDA") and granted Priority Review with a Prescription Drug User Fee Act ("PDUFA") goal date of July 17, 2026, for gedatolisib in HR+/HER2-/PIK3CA wild-type ("WT") advanced breast cancer ("ABC")Results from PIK3CA WT cohort of Phase 3 VIKTORIA-1 study of gedatolisib regimens in HR+/HER2- ABC published in Journal of Clinical OncologyTopline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 study are expected to be released in the second quarter of 2026Management to host webcast and conference call today, March 25, 2026, at 4:30 p.m. EDT MINNEAPOLIS, March 25, 2026 (GLOBE NEWSWIRE) -- Celcu
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Celcuity Inc.SCHEDULE 13D/A - Celcuity Inc. (0001603454) (Subject)
- PRCelcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference CallMINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2025 after the market closes on Wednesday, March 25, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed usi
- PRCelcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical OncologyAs previously presented, gedatolisib + palbociclib + fulvestrant ("gedatolisib triplet") and gedatolisib + fulvestrant ("gedatolisib doublet") reduced the risk of disease progression or death versus fulvestrant by 76% and 67%, respectively MINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced publication of efficacy and safety results from the PIK3CA wild-type ("WT") cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib, an investigational pan-PI3K/mTORC1/2 inhibitor, in the Journal of Clinical Oncology. The cohort consists of patients with hormon
- PRCelcuity To Participate in Upcoming Investor ConferencesMINNEAPOLIS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the TD Cowen 46th Annual Healthcare Conference at 10:30 a.m. ET on Wednesday, March 4, 2026. A live webcast will be available using this weblink: https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/NYER3h287L9qyxak8BZiq2A fireside chat at the Leerink Global Healthcare Conference at 2:20 p.m. ET on Tuesday, M
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Celcuity Inc.SCHEDULE 13G/A - Celcuity Inc. (0001603454) (Subject)
- INSIDERDirector Romp Charles R was granted 215 shares (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERSEC Form 3 filed by new insider Romp Charles R3 - Celcuity Inc. (0001603454) (Issuer)
- SECCelcuity Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Celcuity Inc. (0001603454) (Filer)
- PRCelcuity Appoints Charles Romp to its Board of DirectorsMINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Charles (Chip) R. Romp to its Board of Directors. Mr. Romp brings over 25 years of experience in the pharmaceutical industry to Celcuity, including leadership of sales teams and commercial organizations in the oncology setting. "Chip brings a wealth of oncology-related commercial expertise to our Board," said Brian Sullivan, Chief Executive Officer and co-founder of Celcuity. "Chip's deep experience commercializing significant oncology drugs will provide valuable insight to Celcuity as
- PRCelcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026MINNEAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026 to be held in New York, New York on February 11-12, 2026. Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, is scheduled for a fireside chat at 9:30 a.m. ET on Wednesday, February 11, 2026. A live webcast of the event will be available using this weblink https://event.summitcast.com/view/kbtj9ZAiVkB78KPZiu5dZ9/2Q8oLmGM98qWAwr5LXWSr8. Alternatively, the live webcast will be accessible from the Investors section of
- INSIDERDirector Dalvey David sold $2,400,538 worth of shares (20,000 units at $120.03) (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- SECSEC Form 144 filed by Celcuity Inc.144 - Celcuity Inc. (0001603454) (Subject)
- PRCelcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast CancerFDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026 MINNEAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that the U.S. Food and Drug Administration ("FDA") has accepted for filing its New Drug Application ("NDA") for gedatolisib in hormone receptor positive ("HR+"), human epidermal growth factor receptor 2 negative ("HER2-"), PIK3CA wild-type advanced breast cancer ("ABC"). The FDA granted Priority Review and assigned a Prescription Drug User Fee Act ("PDUFA") goal date of July 17, 2026. The NDA was submitted under the FDA's Real-Tim
- INSIDERDirector Nigon Richard gifted 19,975 shares, decreasing direct ownership by 18% to 89,035 units (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- SECSEC Form S-3ASR filed by Celcuity Inc.S-3ASR - Celcuity Inc. (0001603454) (Filer)
- PRThe $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer TechIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Biopharma M&A is entering a fever pitch, with precision oncology investments alone exploding to $138 billion as major players scramble to secure proven cancer therapies before their most profitable drugs lose protection[1]. This looming $170 billion "patent cliff" has triggered a massive capital rotation into de-risked platforms that can reach patients and the market within the next 18 to 24 months[2]. This urgent race for registration-ready assets is driving the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), OS Therapies Inc. (NY
- ANALYSTWells Fargo initiated coverage on Celcuity with a new price targetWells Fargo initiated coverage of Celcuity with a rating of Overweight and set a new price target of $126.00
CELC FAQ
7 questionsWhat does Celcuity Inc. do?
Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis...Where does CELC stock trade?
Celcuity Inc. (CELC) is listed on NASDAQ.What sector and industry is CELC in?
Celcuity Inc. operates in the Health Care sector, Medical Specialities industry.When did Celcuity Inc. go public?
Celcuity Inc. (CELC) completed its IPO in 2017.What are analysts saying about CELC?
Celcuity Inc. has had 8 recent analyst actions on file. The most recent action was from Citizens: Mkt Outperform on 2026-04-27. Recent price targets range from $2900.00 to $4000.00.What companies are similar to CELC?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare CELC side-by-side with any of them on Quantisnow.How can I track CELC on Quantisnow?
Quantisnow aggregates Celcuity Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CELC to receive live email and push alerts on every new disclosure.